Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial

GeoVax Labs, Inc. (NASDAQ:GOVX) – Equities researchers at Noble Financial boosted their Q4 2024 EPS estimates for shares of GeoVax Labs in a research note issued to investors on Wednesday, November 20th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings of ($1.00) per share for the quarter, up from their prior forecast of ($1.74). Noble Financial currently has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share. Noble Financial also issued estimates for GeoVax Labs’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($2.22) EPS.

Several other analysts also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Alliance Global Partners assumed coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 target price for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $13.25.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock opened at $2.95 on Friday. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18. The stock has a 50 day moving average price of $2.33 and a two-hundred day moving average price of $2.66.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same period last year, the company earned ($4.80) EPS.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.